To Evaluate Pharmacokinetics (PK) and Safety of Tavapadon in Participants With Severe Renal Impairment Compared to Participants With Normal Renal Function

Study Identifier
CVL-751-1004
CT.gov Identifier
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact
Study Complete

Study Details

Medical Condition
  • Renal Impairment
  • Study Drug
  • Tavapadon
  • Phase
    Phase 1
    Sex
    Female & Male
    Age
    18 - 80 Years

    Protocol Summary

    The primary purpose is to assess the effect of renal impairment on the PK of tavapadon following administration of a single oral dose in participants with severe renal impairment relative to age, body weight, and sex-matched participants with normal renal function.

    Study Locations

    Location
    Status
    Location
    Jacksonville, Florida
    Jacksonville, Florida, United States, 32216
    Status
    Not applicable
    Location
    Miami, Florida
    Miami, Florida, United States, 33147
    Status
    Not applicable
    Location
    Tampa, Florida
    Tampa, Florida, United States, 33603
    Status
    Not applicable